LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

Citation metadata

From: Advances in Therapy(Vol. 25, Issue 9)
Publisher: Springer
Document Type: Report
Length: 427 words

Document controls

Main content

Abstract :

Byline: Kenneth Blum (1,2,3,4,11), Amanda L. C. Chen (5,6), Thomas J. H. Chen (5,6), Patrick Rhoades (7), Thomas J. Prihoda (8), B. William Downs (2), Roger L. Waite (2), Lonna Williams (2), Eric R. Braverman (9,3), Dasha Braverman (3), Vanessa Arcuri (3), Mallory Kerner (3), Seth H. Blum (4), Tomas Palomo (10) Keywords: LG839; neurotransmitters; obesity; reward deficiency syndrome; sugar craving behavior; weight loss Abstract: Introduction This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen(r), Inc., La Jolla, CA, USA). Methods A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed. Results Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P Conclusion If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity. Author Affiliation: (1) Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA (2) LifeGen(r), Inc., La Jolla, California, USA (3) PATH Medical & Research Foundation, New York, New York, USA (4) Synaptamine[TM], Inc., San Antonio, Texas, USA (5) Chang Jung Christian University, Tainan, Taiwan (6) Changhua Christian Hospital, Changhua, Taiwan (7) Comprehensive Obesity Clinic, Modesto, California, USA (8) Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA (9) Department of Neurosurgery, Weill Cornell Medical College, New York, New York, USA (10) Hospital Universitario, 12 de Octubre, Servicio de Psiquiatria Av. Cordoba SN, Madrid, Spain (11) Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, North Carolina, USA (12) Chang Jing Christian University, Tainan, Taiwan Article History: Registration Date: 06/09/2008 Online Date: 09/09/2008

Source Citation

Source Citation   

Gale Document Number: GALE|A228118047